Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-05-18 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于可转债转股价格调整的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the adjustment of the conversion price of its convertible bonds due to dividend distribution and capital increase. It includes specific details about the old and new conversion prices, the effective date, and the formulas used for adjustment. There is no financial statement or comprehensive report content. The document is short (1158 characters) and serves as a formal notification of a capital structure change related to convertible bonds. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-05-18 Chinese
关于调整2021年股票期权激励计划股票期权数量和行权价格的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the 2021 stock option incentive plan, specifically changes in the number of stock options and exercise price. It details board and supervisory meetings, independent director opinions, and legal opinions related to the stock option plan adjustments. The content focuses on corporate governance and management decisions about stock option incentives rather than financial results or earnings. It is not a full financial report, earnings release, or regulatory certification. The document is a formal announcement of management decisions related to stock option plans, which fits best under Board/Management Information (MANG). The document length is 4479 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Therefore, the classification is MANG with high confidence.
2023-05-16 Chinese
关于使用可转债部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 特一药业集团股份有限公司 regarding the use of part of the idle proceeds from a previously issued convertible bond to temporarily supplement working capital. It details the background of the bond issuance, the amount of funds raised, the projects funded, and the company's plan to use up to 90 million RMB of idle funds for working capital purposes temporarily. The document includes opinions from independent directors, the supervisory board, and the sponsoring institution, confirming compliance with regulatory requirements and no change in the original use of funds. The document is a formal disclosure about financing and capital usage rather than a financial report, earnings release, or management discussion. It is not a full financial report or audit but an update on capital usage and financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4168 characters, which is sufficient for a detailed announcement but not a full report like an annual or interim report. Hence, the classification is CAP with high confidence.
2023-05-16 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2021年股票期权激励计划调整股票期权数量和行权价格的法律意见书
Audit Report / Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding adjustments to the stock option incentive plan of a company. It details the approval, authorization, and specific adjustments to the stock option quantities and exercise prices. The document is focused on legal compliance and the legitimacy of the stock option plan adjustments, not on financial results, earnings, or management changes. It is a standalone legal opinion related to a stock option incentive plan adjustment, which fits the category of Audit Report / Information (AR) as it involves legal and regulatory compliance verification rather than a full annual report or other categories like management changes or earnings releases. FY 2022
2023-05-16 Chinese
东莞证券关于特一药业使用可转债部分闲置募集资金暂时补充流动资金的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from Dongguan Securities regarding the use of part of the idle raised funds from convertible bonds by Te Yi Pharmaceutical Group Co., Ltd. It references regulatory approvals, specific bond issuance details, and compliance with Shenzhen Stock Exchange rules. The document focuses on the investigation and confirmation of the company's temporary use of idle raised funds to supplement working capital, including board approvals and independent director opinions. It does not contain financial statements or comprehensive financial data but is a regulatory compliance and verification report related to capital use. The document length is 2905 characters, which is relatively short and more of a formal verification opinion rather than a full financial report or announcement of a report. This fits best under Regulatory Filings (RNS), as it is a compliance-related verification document that does not fit other categories like Capital/Financing Update (CAP) or Audit Report (AR).
2023-05-16 Chinese
关于第五届监事会第九次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the ninth meeting of the fifth Supervisory Board of 特一药业集团股份有限公司. It includes details about the approval of using idle raised funds to temporarily supplement working capital and adjustments to the 2021 stock option incentive plan. The document is a formal announcement of board/committee decisions rather than a full report or financial statement. It does not contain comprehensive financial data or detailed management discussion, nor is it a regulatory filing or certification. The content aligns with announcements related to board or management decisions, specifically resolutions passed by the Supervisory Board. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and focused on meeting resolutions, supporting this classification with high confidence.
2023-05-16 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.